Navigation Links
Gene therapy for metastatic melanoma in mice produces complete remission
Date:11/18/2010

INDIANAPOLIS A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation. The online version is now available.

Indiana University School of Medicine researchers used a modified lentivirus to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic stem cells of mice. Hematopoietic stem cells are the bone marrow cells that produce all blood and immune system cells.

The T cell gene, which recognizes a specific protein found on the surface of melanoma, was isolated and cloned from a patient with melanoma. The gene-modified stems cells were then transplanted back into hosts and found to eradicate metastatic melanoma for the lifetime of the mice.

"We found that the transplantation of gene-modified hematopoietic stem cells results in a new host immune system and the complete elimination of tumor," reported Christopher E. Touloukian, M.D., an assistant professor of surgery and immunology at the IU School of Medicine and a member of the Indiana University Melvin and Bren Simon Cancer Center. "To date, cancer immunotherapies have been hampered by limited and diminishing immune responses over time. We believe this type of translational model opens new doors for patients with melanoma and potentially other cancers by taking advantage of the potent regenerative capacity of hematopoietic stem cells and new advances in gene therapy."

This research was funded by a National Institutes of Health grant.

It has paved the way for a new clinical trial in humans funded by the V Foundation for Cancer Research. The pilot phase I trial will involve treatment of 12 patients and focus primarily on the safety and efficacy of the therapy, said Dr. Touloukian, who is the senior author on the JCI paper and the principal investigator for the clinical study. The clinical trial is expected to begin accruing patients by late 2011.

In 2010, more than 68,000 patients will be diagnosed with melanoma and the disease will be associated with approximately 9,000 deaths. The state of Indiana has the 11th highest rate of melanoma incidence of all 50 states. Current treatments for metastatic melanoma, though exciting and innovative, have been highly toxic and largely unsuccessful with the most patients dying within 6 to 12 months after diagnosis.


'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Neuralstem files FDA application for first drug therapy
2. Combination therapy improves survival time for patients with advanced liver cancer
3. Gene Therapy Shows Potential Against Heart Failure
4. Hearing loss common following radiation therapy for head and neck cancer
5. Targeted therapy reactivates guardian of the genome in resistant cancer
6. GUMC: fMRI predicts outcome to talk therapy in children with an anxiety disorder
7. Colorectal cancer risk increases in prostate cancer patients on androgen deprivation therapy
8. Fracture Risk Seen With Hormone Therapy for Prostate Cancer
9. Menopausal hormone therapy may increase risk of ovarian cancer
10. Side effects of hormonal breast cancer therapy increased; may affect treatment adherence
11. Potential drug therapy for diabetic retinopathy under study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy for metastatic melanoma in mice produces complete remission
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology: